CY1118274T1 - 7-μεθυλ-2-[4-μεθυλ-6-[4-(τριφθορομεθυλ)-φαινυλ]πυριμιδιν-2-υλ]-1,7-διαζασπειρο[4.4]εννεαν-6-ονη - Google Patents
7-μεθυλ-2-[4-μεθυλ-6-[4-(τριφθορομεθυλ)-φαινυλ]πυριμιδιν-2-υλ]-1,7-διαζασπειρο[4.4]εννεαν-6-ονηInfo
- Publication number
- CY1118274T1 CY1118274T1 CY20161101143T CY161101143T CY1118274T1 CY 1118274 T1 CY1118274 T1 CY 1118274T1 CY 20161101143 T CY20161101143 T CY 20161101143T CY 161101143 T CY161101143 T CY 161101143T CY 1118274 T1 CY1118274 T1 CY 1118274T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methyl
- ennean
- diazaspiro
- pyrimidin
- trifluoromethyl
- Prior art date
Links
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 title 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 title 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261650325P | 2012-05-22 | 2012-05-22 | |
| GB201209015A GB201209015D0 (en) | 2012-05-22 | 2012-05-22 | Novel compounds |
| US201361773710P | 2013-03-06 | 2013-03-06 | |
| PCT/GB2013/051335 WO2013175205A1 (en) | 2012-05-22 | 2013-05-22 | Novel Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118274T1 true CY1118274T1 (el) | 2017-06-28 |
Family
ID=46546493
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161101143T CY1118274T1 (el) | 2012-05-22 | 2016-11-09 | 7-μεθυλ-2-[4-μεθυλ-6-[4-(τριφθορομεθυλ)-φαινυλ]πυριμιδιν-2-υλ]-1,7-διαζασπειρο[4.4]εννεαν-6-ονη |
| CY20201100326T CY1123044T1 (el) | 2012-05-22 | 2020-04-07 | Νεες ενωσεις |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100326T CY1123044T1 (el) | 2012-05-22 | 2020-04-07 | Νεες ενωσεις |
Country Status (27)
| Country | Link |
|---|---|
| US (7) | US9309254B2 (OSRAM) |
| EP (3) | EP2861594B1 (OSRAM) |
| JP (3) | JP6169687B2 (OSRAM) |
| KR (2) | KR20200113027A (OSRAM) |
| CN (2) | CN107344942B (OSRAM) |
| AU (3) | AU2013265001B2 (OSRAM) |
| BR (1) | BR112014029280B1 (OSRAM) |
| CA (1) | CA2873956C (OSRAM) |
| CY (2) | CY1118274T1 (OSRAM) |
| DK (2) | DK2861602T3 (OSRAM) |
| EA (1) | EA025579B1 (OSRAM) |
| ES (3) | ES2602193T3 (OSRAM) |
| GB (1) | GB201209015D0 (OSRAM) |
| HR (2) | HRP20161349T1 (OSRAM) |
| HU (2) | HUE049445T2 (OSRAM) |
| IL (4) | IL235805A (OSRAM) |
| IN (1) | IN2014MN02393A (OSRAM) |
| LT (2) | LT2861602T (OSRAM) |
| MX (1) | MX355303B (OSRAM) |
| PL (2) | PL3106464T3 (OSRAM) |
| PT (2) | PT3106464T (OSRAM) |
| RS (2) | RS60368B1 (OSRAM) |
| SG (2) | SG11201407755UA (OSRAM) |
| SI (2) | SI3106464T1 (OSRAM) |
| SM (2) | SMT202000210T1 (OSRAM) |
| WO (2) | WO2013175205A1 (OSRAM) |
| ZA (1) | ZA201408253B (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201209015D0 (en) | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
| KR20200060404A (ko) * | 2017-09-28 | 2020-05-29 | 바이오젠 인크. | 신규한 염 |
| CN111526874A (zh) * | 2017-10-10 | 2020-08-11 | 生物基因公司 | 用于制备螺环衍生物的方法 |
| WO2022133097A1 (en) * | 2020-12-17 | 2022-06-23 | Biogen Ma Inc. | Synthesis of compounds that modulate use-dependent voltage-gated sodium channels |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2078718A1 (en) * | 2002-07-05 | 2009-07-15 | Targacept, Inc. | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof |
| US8143306B2 (en) | 2005-10-10 | 2012-03-27 | Convergence Pharmaceuticals Limited | Methods of treating bipolar disorders |
| TW200730494A (en) | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| TW200728258A (en) | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| GB0520578D0 (en) * | 2005-10-10 | 2005-11-16 | Glaxo Group Ltd | Novel compounds |
| WO2007042250A1 (en) | 2005-10-10 | 2007-04-19 | Glaxo Group Limited | Prolinamide derivatives as sodium channel modulators |
| US7683083B2 (en) * | 2005-10-12 | 2010-03-23 | Vertex Pharmaceuticals Incorporated | Biphenyl derivatives as modulators of voltage gated ion channels |
| US7998959B2 (en) * | 2006-01-12 | 2011-08-16 | Incyte Corporation | Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
| MX2009003874A (es) | 2006-10-12 | 2009-04-22 | Xenon Pharmaceuticals Inc | Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos. |
| CL2007002953A1 (es) | 2006-10-12 | 2008-02-01 | Xenon Pharmaceuticals Inc | Compuestos derivados de espiro-oxindol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, prurito, hiperplasia prostatica benigna, hipercolesterolemia. |
| CN101641099A (zh) | 2007-01-24 | 2010-02-03 | 葛兰素集团有限公司 | 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物 |
| GB0701365D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0701366D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0706630D0 (en) * | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
| AR077252A1 (es) * | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| WO2011029762A1 (en) | 2009-09-14 | 2011-03-17 | Convergence Pharmaceuticals Limited | Process for preparing alpha-carboxamide derivatives |
| GB201122113D0 (en) * | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| TWI625046B (zh) * | 2012-03-21 | 2018-05-21 | 內數位專利控股公司 | 在無線網路中行動站贊助方法及裝置 |
| GB201209015D0 (en) | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
| GB201209670D0 (en) | 2012-05-31 | 2012-07-18 | Convergence Pharmaceuticals | Novel compounds |
-
2012
- 2012-05-22 GB GB201209015A patent/GB201209015D0/en not_active Ceased
-
2013
- 2013-05-22 US US14/403,480 patent/US9309254B2/en not_active Expired - Fee Related
- 2013-05-22 US US14/403,473 patent/US9376445B2/en not_active Expired - Fee Related
- 2013-05-22 PL PL16177700T patent/PL3106464T3/pl unknown
- 2013-05-22 ES ES13725438.9T patent/ES2602193T3/es active Active
- 2013-05-22 RS RS20200393A patent/RS60368B1/sr unknown
- 2013-05-22 RS RS20160960A patent/RS55415B1/sr unknown
- 2013-05-22 DK DK13725438.9T patent/DK2861602T3/en active
- 2013-05-22 CN CN201710522297.1A patent/CN107344942B/zh not_active Expired - Fee Related
- 2013-05-22 EP EP13725439.7A patent/EP2861594B1/en not_active Not-in-force
- 2013-05-22 SI SI201331705T patent/SI3106464T1/sl unknown
- 2013-05-22 EA EA201492169A patent/EA025579B1/ru unknown
- 2013-05-22 PT PT161777008T patent/PT3106464T/pt unknown
- 2013-05-22 LT LTEP13725438.9T patent/LT2861602T/lt unknown
- 2013-05-22 ES ES16177700T patent/ES2782088T3/es active Active
- 2013-05-22 PT PT137254389T patent/PT2861602T/pt unknown
- 2013-05-22 JP JP2015513266A patent/JP6169687B2/ja not_active Expired - Fee Related
- 2013-05-22 KR KR1020207027461A patent/KR20200113027A/ko not_active Ceased
- 2013-05-22 DK DK16177700.8T patent/DK3106464T3/da active
- 2013-05-22 EP EP13725438.9A patent/EP2861602B1/en active Active
- 2013-05-22 CA CA2873956A patent/CA2873956C/en active Active
- 2013-05-22 SG SG11201407755UA patent/SG11201407755UA/en unknown
- 2013-05-22 MX MX2014014274A patent/MX355303B/es active IP Right Grant
- 2013-05-22 SG SG10201703527WA patent/SG10201703527WA/en unknown
- 2013-05-22 CN CN201380038180.6A patent/CN104640867B/zh not_active Expired - Fee Related
- 2013-05-22 WO PCT/GB2013/051335 patent/WO2013175205A1/en not_active Ceased
- 2013-05-22 BR BR112014029280-9A patent/BR112014029280B1/pt not_active IP Right Cessation
- 2013-05-22 HU HUE16177700A patent/HUE049445T2/hu unknown
- 2013-05-22 LT LTEP16177700.8T patent/LT3106464T/lt unknown
- 2013-05-22 KR KR1020147035444A patent/KR102161101B1/ko not_active Expired - Fee Related
- 2013-05-22 ES ES13725439.7T patent/ES2602308T3/es active Active
- 2013-05-22 IN IN2393MUN2014 patent/IN2014MN02393A/en unknown
- 2013-05-22 PL PL13725438T patent/PL2861602T3/pl unknown
- 2013-05-22 HU HUE13725438A patent/HUE031664T2/en unknown
- 2013-05-22 SI SI201330339A patent/SI2861602T1/sl unknown
- 2013-05-22 WO PCT/GB2013/051336 patent/WO2013175206A1/en not_active Ceased
- 2013-05-22 EP EP16177700.8A patent/EP3106464B1/en active Active
- 2013-05-22 AU AU2013265001A patent/AU2013265001B2/en not_active Ceased
- 2013-05-22 JP JP2015513267A patent/JP2015517562A/ja not_active Withdrawn
- 2013-05-22 SM SM20200210T patent/SMT202000210T1/it unknown
- 2013-05-22 HR HRP20161349TT patent/HRP20161349T1/hr unknown
-
2014
- 2014-11-11 ZA ZA2014/08253A patent/ZA201408253B/en unknown
- 2014-11-20 IL IL235805A patent/IL235805A/en active IP Right Grant
-
2016
- 2016-02-15 US US15/043,920 patent/US20160184306A1/en not_active Abandoned
- 2016-05-25 US US15/163,845 patent/US9737536B2/en not_active Expired - Fee Related
- 2016-11-09 CY CY20161101143T patent/CY1118274T1/el unknown
- 2016-11-21 SM SM201600421T patent/SMT201600421B/it unknown
-
2017
- 2017-03-01 AU AU2017201421A patent/AU2017201421B2/en not_active Ceased
- 2017-04-30 IL IL252033A patent/IL252033B/en active IP Right Grant
- 2017-06-28 JP JP2017125716A patent/JP6378404B2/ja not_active Expired - Fee Related
- 2017-07-11 US US15/646,552 patent/US10010551B2/en active Active
-
2018
- 2018-03-07 AU AU2018201653A patent/AU2018201653B2/en not_active Ceased
- 2018-06-27 US US16/019,886 patent/US10485801B2/en not_active Expired - Fee Related
-
2019
- 2019-10-17 US US16/655,970 patent/US20200289508A1/en not_active Abandoned
- 2019-12-11 IL IL271330A patent/IL271330B/en active IP Right Grant
-
2020
- 2020-04-06 HR HRP20200580TT patent/HRP20200580T1/hr unknown
- 2020-04-07 CY CY20201100326T patent/CY1123044T1/el unknown
-
2021
- 2021-02-02 IL IL280595A patent/IL280595A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125613T1 (el) | 4-ιμιδαζοπυριδαζιν-1-υλ-βενζαμιδια και 4- ιμιδαζοτριαζιν-1-υλ-βενζαμιδια ως αναστολεις βτκ | |
| CY1125436T1 (el) | Αναστολεις dna-pk | |
| CY1124928T1 (el) | Αναστολεις πυραζολυλο κινοξαλινο κινασης | |
| CY1124311T1 (el) | Παρεμποδιστες dna-pk | |
| CY1121170T1 (el) | Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων | |
| CY1121793T1 (el) | Εκλεκτικοι αναστολεις pi3k δελτα | |
| CY1121934T1 (el) | Αντισωματα anti-fcrn | |
| CY1123953T1 (el) | Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης | |
| CY1119123T1 (el) | Δις-αρυλοσυζευγμενες αρυλοτριαζολονες και η χρηση τους | |
| NI201300112A (es) | Composición que comprende aflibercept, ácido folínico, 5 - fluorouracilo (5 - fu) e irinotecano ( folfiri). | |
| CY1118834T1 (el) | Συγχωνευμενες ετεροκυκλικες ενωσεις ως αναστολεις πρωτεϊνικης κινασης | |
| CY1116315T1 (el) | Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3 | |
| CY1123295T1 (el) | Κρυσταλλικες μορφες της 5-χλωρο-ν4-[-2-(διμεθυλοφωσφορυλο) φαινυλο]-ν2-{2-μεθοξυ-4-[4-(4-μεθυλοπιπεραζιν-1-υλο)πιπεριδιν- 1-υλο]πυριμιδινο-2,4-διαμινης | |
| CY1117372T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους | |
| CY1118416T1 (el) | Υποκατεστημενες 4-φαινυλο-πυριδινες για τη θεραπεια ασθενειων που σχετιζονται με τον νκ-1 υποδοχεα | |
| CY1116057T1 (el) | Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3 | |
| JOP20140114B1 (ar) | مركبات حلقية غير متجانسة واستخداماتها | |
| CY1123490T1 (el) | Συνθεσεις που προερχονται απο χιτοζανη | |
| CY1118900T1 (el) | Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων | |
| UA111098C2 (uk) | Проліки адреномедуліну на основі поліетиленгліколю і їх застосування | |
| CY1118274T1 (el) | 7-μεθυλ-2-[4-μεθυλ-6-[4-(τριφθορομεθυλ)-φαινυλ]πυριμιδιν-2-υλ]-1,7-διαζασπειρο[4.4]εννεαν-6-ονη | |
| EA201590962A1 (ru) | Новые соединения | |
| CY1119391T1 (el) | Παραγωγα οξαζολιδιν-2- ονη- πυριμιδινης | |
| CY1120185T1 (el) | Υποκατεστημενα πυριδινικα παραγωγα χρησιμα ως αναστολεις c-fms κινασης | |
| UY35746A (es) | Derivados de fenilalanina sustituidos |